Cargando…
Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches
[Image: see text] Fibrodysplasia ossificans progressiva (FOP) is a rare but severe genetic disorder in which acute inflammation elicits progressive heterotopic ossification in the muscles, tendons, and ligaments. Classic FOP is caused by the R206H mutation in ALK2/ACVR1. While several activin recept...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254505/ https://www.ncbi.nlm.nih.gov/pubmed/32478230 http://dx.doi.org/10.1021/acsomega.9b04245 |
_version_ | 1783539552943603712 |
---|---|
author | Sato, Tomohiro Sekimata, Katsuhiko Sakai, Naoki Watanabe, Hisami Mishima-Tsumagari, Chiemi Taguri, Tomonori Matsumoto, Takehisa Fujii, Yoshifumi Handa, Noriko Tanaka, Akiko Shirouzu, Mikako Yokoyama, Shigeyuki Hashizume, Yoshinobu Miyazono, Kohei Koyama, Hiroo Honma, Teruki |
author_facet | Sato, Tomohiro Sekimata, Katsuhiko Sakai, Naoki Watanabe, Hisami Mishima-Tsumagari, Chiemi Taguri, Tomonori Matsumoto, Takehisa Fujii, Yoshifumi Handa, Noriko Tanaka, Akiko Shirouzu, Mikako Yokoyama, Shigeyuki Hashizume, Yoshinobu Miyazono, Kohei Koyama, Hiroo Honma, Teruki |
author_sort | Sato, Tomohiro |
collection | PubMed |
description | [Image: see text] Fibrodysplasia ossificans progressiva (FOP) is a rare but severe genetic disorder in which acute inflammation elicits progressive heterotopic ossification in the muscles, tendons, and ligaments. Classic FOP is caused by the R206H mutation in ALK2/ACVR1. While several activin receptor-like kinase 2 (ALK2) inhibitors were found to be efficacious in animal models of FOP, most of the ALK2 (R206H) inhibitors lacked sufficient oral bioavailability for efficacy. Previously, the synthesis of a series of novel bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitors that achieved both substantial potency and an improved ADMET profile was reported. In the present study, the detailed procedure of the in silico approach employed to identify the initial bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitor RK-59638 and the analysis of the ALK2 (R206H) RK-59638 complex structure to guide the synthetic optimization of the chemical series, obtaining RK-71807 showing improved potency and metabolic stability, were described. According to the initial in silico screening, the screening efficiencies and chemical diversity of the hit compounds of both ligand-based and structure-based methods were evaluated. Then, X-ray structures of ALK2 (R206H) and the inhibitors were analyzed to assess the structure–activity relationships of the synthesized compounds. The 3D-RISM analysis indicated the existence of the additional hydrogen bond via water molecules restricting the attachment point in the pyrazole scaffold. The quantum mechanics calculation of the newly determined ALK2 (R206H) RK-71807 complex structure using a fragment molecular orbital method and pair interaction energy decomposition analysis was employed to evaluate the interaction energies between the inhibitor and each of the amino acid residues and decompose them to electrostatic, exchange-repulsion, and charge transfer energies. The pattern of decomposed interaction energies was then compared to that formed by RK-59638 and LDN-193189 to investigate the structural basis of ALK2 (R206H) inhibition. |
format | Online Article Text |
id | pubmed-7254505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-72545052020-05-29 Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches Sato, Tomohiro Sekimata, Katsuhiko Sakai, Naoki Watanabe, Hisami Mishima-Tsumagari, Chiemi Taguri, Tomonori Matsumoto, Takehisa Fujii, Yoshifumi Handa, Noriko Tanaka, Akiko Shirouzu, Mikako Yokoyama, Shigeyuki Hashizume, Yoshinobu Miyazono, Kohei Koyama, Hiroo Honma, Teruki ACS Omega [Image: see text] Fibrodysplasia ossificans progressiva (FOP) is a rare but severe genetic disorder in which acute inflammation elicits progressive heterotopic ossification in the muscles, tendons, and ligaments. Classic FOP is caused by the R206H mutation in ALK2/ACVR1. While several activin receptor-like kinase 2 (ALK2) inhibitors were found to be efficacious in animal models of FOP, most of the ALK2 (R206H) inhibitors lacked sufficient oral bioavailability for efficacy. Previously, the synthesis of a series of novel bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitors that achieved both substantial potency and an improved ADMET profile was reported. In the present study, the detailed procedure of the in silico approach employed to identify the initial bis-heteroaryl pyrazole-based ALK2 (R206H) inhibitor RK-59638 and the analysis of the ALK2 (R206H) RK-59638 complex structure to guide the synthetic optimization of the chemical series, obtaining RK-71807 showing improved potency and metabolic stability, were described. According to the initial in silico screening, the screening efficiencies and chemical diversity of the hit compounds of both ligand-based and structure-based methods were evaluated. Then, X-ray structures of ALK2 (R206H) and the inhibitors were analyzed to assess the structure–activity relationships of the synthesized compounds. The 3D-RISM analysis indicated the existence of the additional hydrogen bond via water molecules restricting the attachment point in the pyrazole scaffold. The quantum mechanics calculation of the newly determined ALK2 (R206H) RK-71807 complex structure using a fragment molecular orbital method and pair interaction energy decomposition analysis was employed to evaluate the interaction energies between the inhibitor and each of the amino acid residues and decompose them to electrostatic, exchange-repulsion, and charge transfer energies. The pattern of decomposed interaction energies was then compared to that formed by RK-59638 and LDN-193189 to investigate the structural basis of ALK2 (R206H) inhibition. American Chemical Society 2020-05-12 /pmc/articles/PMC7254505/ /pubmed/32478230 http://dx.doi.org/10.1021/acsomega.9b04245 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Sato, Tomohiro Sekimata, Katsuhiko Sakai, Naoki Watanabe, Hisami Mishima-Tsumagari, Chiemi Taguri, Tomonori Matsumoto, Takehisa Fujii, Yoshifumi Handa, Noriko Tanaka, Akiko Shirouzu, Mikako Yokoyama, Shigeyuki Hashizume, Yoshinobu Miyazono, Kohei Koyama, Hiroo Honma, Teruki Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches |
title | Structural Basis of Activin Receptor-Like Kinase 2
(R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for
the Treatment of Fibrodysplasia Ossificans Progressiva Identified
by the Integration of Ligand-Based and Structure-Based Drug Design
Approaches |
title_full | Structural Basis of Activin Receptor-Like Kinase 2
(R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for
the Treatment of Fibrodysplasia Ossificans Progressiva Identified
by the Integration of Ligand-Based and Structure-Based Drug Design
Approaches |
title_fullStr | Structural Basis of Activin Receptor-Like Kinase 2
(R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for
the Treatment of Fibrodysplasia Ossificans Progressiva Identified
by the Integration of Ligand-Based and Structure-Based Drug Design
Approaches |
title_full_unstemmed | Structural Basis of Activin Receptor-Like Kinase 2
(R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for
the Treatment of Fibrodysplasia Ossificans Progressiva Identified
by the Integration of Ligand-Based and Structure-Based Drug Design
Approaches |
title_short | Structural Basis of Activin Receptor-Like Kinase 2
(R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for
the Treatment of Fibrodysplasia Ossificans Progressiva Identified
by the Integration of Ligand-Based and Structure-Based Drug Design
Approaches |
title_sort | structural basis of activin receptor-like kinase 2
(r206h) inhibition by bis-heteroaryl pyrazole-based inhibitors for
the treatment of fibrodysplasia ossificans progressiva identified
by the integration of ligand-based and structure-based drug design
approaches |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254505/ https://www.ncbi.nlm.nih.gov/pubmed/32478230 http://dx.doi.org/10.1021/acsomega.9b04245 |
work_keys_str_mv | AT satotomohiro structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT sekimatakatsuhiko structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT sakainaoki structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT watanabehisami structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT mishimatsumagarichiemi structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT taguritomonori structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT matsumototakehisa structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT fujiiyoshifumi structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT handanoriko structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT tanakaakiko structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT shirouzumikako structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT yokoyamashigeyuki structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT hashizumeyoshinobu structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT miyazonokohei structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT koyamahiroo structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches AT honmateruki structuralbasisofactivinreceptorlikekinase2r206hinhibitionbybisheteroarylpyrazolebasedinhibitorsforthetreatmentoffibrodysplasiaossificansprogressivaidentifiedbytheintegrationofligandbasedandstructurebaseddrugdesignapproaches |